Skip to main content

Table 3 Baseline demographics of patient population and comparison of pulmonary function tests (PFTs), lung transplantation or death, and transplant-free survival time between PPI treatment group and control group

From: Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis

Items PPI treatment group (n = 130) Control group (n = 85) p-value
Age (years) 66 (55–73) 67 (61–76) 0.112
Male gender 81 (62.3) 54 (63.5) 0.856
Ethnicity (white, non-hispanic) 93 (71.5) 69 (81.2) 0.109
Surgical lung biopsy 61 (46.9) 35 (41.2) 0.407
BMI (kg/m2) 27.7 (24.5–32.5) 27.8 (25.4–30.8) 0.945
Smoking history (pack years) 6 (0–25) 5 (0–30) 0.850
Pulmonary hypertension 22 (16.9) 19 (22.4) 0.333
Lung function test
 FVC% predicted 65 (54–75) 62 (51–77) 0.440
 DLCO% predicted 52 (42–65) 47 (36–57) 0.064
Patients with lung transplantation or death 77 (59.2) 63 (74.1) 0.025
Transplant-free survival (years) 3.4 (1.8–5.3) 2.0 (1.2–4.1) 0.001
  1. Data are presented as median (25th–75th percentile) or number (percentage).